P115 – Human recombinant ACE2 as a universal agent to block SARS-CoV-2 variants

11. Virologi

Ali Mirazimi1

1 Sva

Bakgrund: The recent emergence of multiple SARS-CoV-2 variants has caused considerable concern due to reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is therefore paramount to develop therapeutic strategies that inhibit all known and future SARS-CoV-2 variants.

Metod: 2 different cell lines and state-of-arts 3D organoids infection models used to demonstrate the antiviral activity of Recombinant soluable human angiotensin converting enzyme (ACE)- 2.

Resultat: Here we report that all SARS-CoV-2 variants analyzed, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced binding affinity to clinical grade and phase 2 tested recombinant human soluble ACE2. Effective inhibition of infections with SARS-CoV-2 variants was validated and confirmed in two independent laboratories. 

Slutsats: Here we report that all SARS-CoV-2 variants analyzed, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced binding affinity to clinical grade and phase 2 tested recombinant human soluble ACE2 (APN01). Importantly, soluble ACE2 neutralized infection by multiple VOC strains with markedly enhanced potency when compared to reference SARS-CoV-2 isolates. These data show that SARS-CoV-2 variants that have emerged around the world, including current VOC and several variants of interest, can be inhibited by soluble ACE2, providing proof of principle of a pan-SARS-CoV-2 therapeutic. inhibited by soluble ACE2, providing proof of principle of a pan-SARS-CoV-2 therapeutic.